Gil Morgan, MD
@weoncologists
Followers
16K
Following
38K
Media
2K
Statuses
27K
Clinical Oncologist from Texas🇺🇸Director of @OncoAlert 🚨 Proudly NIH, NCI & MDA trained. An ounce of prevention equals a pound of cure. Views are own🌏
San Antonio, TX
Joined May 2009
A pleasure to publish this at @CD_AACR w/some AMAZING @OncoAlert 🚨colleagues/friends. SoMe has immense potential in ALL areas of medicine⚕️. ☑️raises awareness on trials.☑️promotes cancer prevention ☑️amplifies oncology info.☑️enables diverse viewpoints.
14
94
250
RT @OncoAlert: The OncoAlert🚨Weekly Round Up .Covering the TOP of the week July 4-10, 2025 . REGISTER at OR h….
0
19
0
RT @GaiaGriguolo: PALMARES-2 study @Annals_Oncology. Real-world effectiveness of first-line palbociclib, ribociclib or abemaciclib plus ET….
0
2
0
RT @MarioBalsaMD: 🚀 Final OS results from the phase III TALAPRO-2 trial now published @TheLancet!. Talazoparib + enzalutamide improved OS a….
0
5
0
RT @Icro_Meattini: Proud to share our @ESTRO_RT manifesto published in @RO_GreenJournal . A call to reposition radiation oncology at the h….
0
10
0
RT @mirrorsmed: Molecular characterization of residual muscle-invasive bladder cancer identifies a scar-like transcriptomicprofile with fav….
0
5
0
RT @APCCC_Lugano: Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair–deficient Metastatic Castration-resistant Pro….
0
6
0
RT @APCCC_Lugano: An integrated proteomic portrait of prostate cancer progression. This study uses proteomic profi….
0
5
0
RT @mirrorsmed: Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management an….
0
9
0
RT @realbowtiedoc: Over the next 2 weeks hope to do some quick #video summaries of our #Top10Tips paper for #hpm on #survonc. Hope you enjo….
0
20
0
RT @MarioBalsaMD: 📄 In @Cancer_Cell: excercise reshapes gut microbiota, boosting ICI response in melanoma: ▪️↑ For….
0
11
0
RT @realbowtiedoc: Anticipating this #GIonc study since #ESMO24 - LEANOX in @JCO_ASCO. #Lean body mass based #oxaliplatin dosing in stage I….
0
10
0
RT @ElisaAgostinett: The last @OncoAlert newsletter is out📩 today featuring the BRCA BCY paper on breastfeeding in BRCA-mut #breastcancer!….
0
6
0
RT @OncoAlert: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous #OvarianCancer : Primary Analysis of ENGOT-OV….
0
4
0
RT @mirrorsmed: Early bird registration is OPEN! . Don’t miss your chance to join the RENALC-BLADDR-PROSCA 2025 hybrid global forum on GU O….
0
5
0
RT @mirrorsmed: Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial. In t….
0
10
0
RT @APCCC_Lugano: Long-Term Outcomes After Guideline-Recommended Treatment of Men With Prostate Cancer. In a natio….
0
6
0
RT @nataliagandur: 🌟Therapeutic Targeting of MMR-Deficient Cancers🌟.🖋️ Paul Johannet, Benoit Rousseau, Carol Aghajanian,.@MikeFooteMD @MSKC….
0
15
0
RT @Abdallah81MD: 🧵7/🧠 Takeaways:.🔹 Nanobody CAR-T is a promising new frontier.🔹 Strong activity in tough-to-treat subtypes.🔹 Infection ris….
0
5
0
RT @Erman_Akkus: 📋Environmental Risk Factors for Liver Cancer.@HEP_Journal . 👉 #cancer #oncology #liver #MedX @Onco….
0
10
0